Periscope Capital’s Japer Therapeutics Warrants JSPRW Stock Holding History

Periscope Capital’s Portfolio JSPRW Stock Details JSPRW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-41,368	Closed	-$48K	–	368
2020 Q3	$48K	Sell	41,368 -8,832	-18%	-$8.93K	﹤0.01%	286
2020 Q2	$52K	Buy	+50,200	New	+$31.3K	﹤0.01%	229

Other funds holding JSPRW

Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return

Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return

P. Schoenfeld Asset Management (PSAM) New York $184M AUM 97.09% 1-Year Est. Return

Sage Rock Capital Management New York $22.3M AUM 4.09% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Picton Mahoney Asset Management Toronto, Ontario, Canada $13.5B AUM 50.48% 1-Year Est. Return

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Altium Capital Management New York $42M AUM

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

Periscope Capital's JSPRW Position: Q4 2020 in Review

Periscope Capital sold out of Japer Therapeutics Warrants (JSPRW) in Q4 2020, closing a stake of 41,368 shares — an estimated $48K sold.

Periscope Capital first reported a position in JSPRW in Q2 2020 and held it in 2 quarters. The position peaked at $52K in Q2 2020. 35 funds tracked by Wall St. Rank hold JSPRW as of Q4 2020.

Periscope Capital reported no remaining Japer Therapeutics Warrants position as of Q4 2020 after selling out during the quarter.
Periscope Capital sold 41,368 Japer Therapeutics Warrants shares in Q4 2020, an estimated $48K.
Periscope Capital first reported a position in Japer Therapeutics Warrants in Q2 2020 and held it in 2 quarters.
Periscope Capital's Japer Therapeutics Warrants position peaked at $52K in Q2 2020.
35 funds tracked by Wall St. Rank held Japer Therapeutics Warrants as of Q4 2020.

Based on Periscope Capital's 13F filing for Q4 2020, filed 10 Feb 2021.